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We present a case of a solitary neurofibroma involving the right posterior shoulder of a
69-year-old man with degeneration into a massive, malignant peripheral nerve sheath
tumor measuring more than 3 times the average reported size. The radiographic, magnetic
resonance imaging, and computed tomographic features are compared with the gross
appearance and pathology.
Copyright © 2016, the Authors. Published by Elsevier Inc. under copyright license from the
University of Washington. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
We present a case of a solitary neurofibroma involving the
right posterior shoulder of a 69-year-old man that over the
span of approximately 3 years underwent degeneration into a
massive, malignant peripheral nerve sheath tumor (MPNST),
ultimately measuring more than 3 times the average reported
size. The radiographic, magnetic resonance imaging (MRI),
and computed tomographic (CT) features are described and
demonstrated, as is the gross appearance and pathology.Case report
A 69-year-old Caucasian man initially noticed a painful, right
posterior shoulder mass in 2012, at which time he presented
to an outside institution for evaluation. Shoulder radiography
was performed and demonstrated a large soft-tissue masslared that no competing
and).
blished by Elsevier Inc. u
ND license (http://creativwithout appreciable calcification or tumor matrix (Fig. 1).
An MRI was also obtained and more clearly defined a 10-cm
by 5-cm by 5-cm homogeneous lesion within the posterior
and superior soft tissues of the right shoulder that
appeared hypointense on T1-weighted imaging, hyperintense
on fluid sensitive sequences, and with homogenous
internal enhancement after the administration of intravenous
gadolinium-based contrast (Figs. 2A-D). The mass was sub-
sequently biopsied under image guidance, and pathology was
consistent with a neurofibroma.
The patient presented to our institution approximately 3
years removed from initial work-up, reporting the mass had
undergone a recent rapid increase in size and with worsening
associated pain. The patient’s history was otherwise
noncontributory; specifically, there was no history of neuro-
fibromatosis or report of prior malignancy, surgery, or trauma
to the affected region. On physical examination, the mass
appeared superficial to the right trapezius muscle, in keepinginterests exist.
nder copyright license from the University of Washington. This is
ecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1 e Initial presentation. Frontal radiograph
demonstrates large soft-tissue densitymass superior to the
trapeziuswithout appreciable calcification or tumormatrix.
Fig. 2 e Initial presentation. (A) Coronal short-tau inversion rec
mass superior to the trapezius. (B) Axial T1-weighted MRI demo
trapezius. (C) Axial T2-weighted fat-suppressed MRI demonstra
trapezius. (D) Axial T1-weighted fat-suppressed post-intraveno
ovoid mass with homogeneous internal enhancement.
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without fungation (Figs. 3A and B). His right shoulder range of
motion was preserved, and his right upper extremity was
neurovascularly intact.
A repeat MRI was obtained at our institution and demon-
strated a 20-cm by 18-cm by 15-cm mass hypointense on
T1-weighted imaging, heterogeneously hyperintense on fluid
sensitive sequences, with heterogeneous internal enhance-
ment after the administration of intravenous gadolinium-
based contrast, and with numerous flow voids attributable
to multiple large vessels (Figs. 4A-D). Computed tomographic
imaging performed at an outside institution in 2015 just before
his referral was reviewed, and notable for a lack of soft-tissue
calcification or appreciable internal tumor matrix (Fig. 5).
Given the increase in size and progressive pain, an
ultrasound-guided biopsy was performed, and pathology
confirmed a spindle cell sarcoma consistentwithMPNST (Figs.
6A and B).
The patient was discussed at the multidisciplinary tumor
board at our institution after biopsy. This panel includes the
department of pathology, oncology, orthopedic oncology, and
radiology. Consensus regardingmanagementwas established,
and included neoadjuvant radiation, followed by tumorovery (STIR) MRI demonstrates a large hyperintense ovoid
nstrates a large hypointense ovoid mass superficial to the
tes a large hyperintense ovoid mass superficial to the
us gadolinium-based contrast MRI demonstrates a large
Fig. 3 e Second presentation, 3 years later. (A) Clinical photograph shows large mass involving the superior shoulder with
overlying attenuated skin. (B) Clinical photograph shows large mass involving the superior shoulder with overlying
attenuated skin.
Fig. 4 e Second presentation, 3 years later. (A) Coronal short-tau inversion recovery (STIR) MRI demonstrates significant
interval size increase of a heterogeneously hyperintense shoulder mass (vascular flow voids denoted by arrows). (B) Axial
T1-weighted MRI demonstrates significant interval size increase of a hypointense shoulder mass. (C) Axial T2-weighted
fat-suppressed MRI demonstrates significant interval size increase of a heterogeneously hyperintense shoulder mass.
(D) Axial T1-weighted fat-suppressed post-intravenous gadolinium-based contrast MRI demonstrates heterogeneous
enhancement of a right shoulder mass.
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Fig. 5 e Second presentation, 3 years later. Intravenous
iodinated contrast-enhanced CT coronal soft-tissue
window shows no soft-tissue calcification or tumor matrix
within the mass.
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total dose of 5,000 cGy of radiation in 25 fractions to his right
shoulder mass. A follow-up postradiotherapy MRI demon-
strated a marginal increase in tumor size, with a concomitant
decrease in internal enhancement, suggesting a modest posi-
tive therapeutic response with treatment-related necrosis.
After completion of radiation therapy, the mass was sur-
gically resected by the orthopedic oncology service at our
institution and weighed 4.5 kg (Figs. 7A-C). The plastic surgeryFig. 6 e Second presentation, 3 years later. (A) Photomicrograph
shows pleomorphic spindle cells arranged in a vague storiform
hematoxylin and eosin stain demonstrates rare mitoses.service closed the large resultant wound with a pedicled la-
tissimus dorsi flap and split-thickness skin graft.Discussion
Neurofibromas are benign peripheral nerve sheath tumors
composed of Schwann cells, fibroblasts, and perineurial cells.
Most neurofibromas are solitary and occur in individuals 20-30
years of age and without a history of neurofibromatosis,
although there is a strong association between neurofibro-
matosis and the development of neurofibromas [1]. Specif-
ically, nearly 100% of patients with multiple neurofibromas
have neurofibromatosis type 1 (NF1) [1].
Neurofibromas are classified as either cutaneous or intra-
neural, with the former arising from small intradermal
nerves. The plexiform neurofibroma refers to a subtype of
neurofibroma with a unique pathologic growth pattern that
may be grossly apparent (pedunculated dermal and subcu-
taneous tumors that appear thick, wormy, and baggy) or only
evident on microscopic examination [2]. This specific subset
of neurofibroma is considered pathognomonic for NF1, and
carries a relatively high risk of malignant degeneration,
occurring in up to 13% [2,3].
On MRI, neurofibromas typically appear isointense to
peripheral nerves on T1-weighted imaging and demonstrate
peripheral hyperintensity with central hypointense or iso-
intense signal on T2-weighted imaging. Contrast enhance-
ment, if present, is typically homogeneous and mild.
Malignant degeneration of a neurofibroma is often clini-
cally manifest by a rapid increase in tumor size or sudden
onset of pain or neurovascular symptoms in a previously
asymptomatic patient. On average, MPNSTs measure 6 cm;
this is in contrast to our case in which the massive tumor
measured up to 20 cm in maximal dimension [4]. The most
common location of a MPNST is the supraclavicular brachial
plexus [3]. Notably, approximately 50% of MPNSTs arise in
patients without NF1 [3,5].
On MRI, MPNSTs appear heterogeneously hyperintense on
fluid sensitive sequences, with intense heterogeneous
enhancement after the administration of gadolinium-based
intravenous contrast, and exhibit other features typical of aat 10£ magnification with hematoxylin and eosin stain
pattern. (B) Photomicrograph at 60£ magnification with
Fig. 7 e Intraoperative imaging. (A) Large mass involving the superior right shoulder with overlying attenuated skin
acquired just before surgical resection. (B) Large MPNSTweighing 4.5 kg. (C) Large defect at the right shoulder after resection
of a massivemalignant peripheral nerve sheath tumor. The defect was subsequently closed with a pedicled latissimus dorsi
flap and split-thickness skin graft.
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tures and indistinct margins [6].
Treatment of a MPNST is dependent on tumor location,
with peripheral-extremity lesions typically requiring local
excision alone. More proximal lesions may require amputa-
tion, although there is a recent trend toward limb sparing
resection [3]. Adjuvant therapies such as external beam radi-
ation, brachytherapy seeds, or chemotherapy may be per-
formed dependent on final pathology, margins, and location.
Prognosis is variable, but a review of 221 patients who
underwent local resection for MPNST demonstrated a 10-year
disease-specific mortality rate of 43% [7].r e f e r e n c e s
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